National Cancer Control Institute, National Cancer Center, Goyang, Korea.
Copyright © 2012 by the Korean Cancer Association
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
| Cancer | Target population | Interval | Test |
|---|---|---|---|
| Stomach | Age 40 and over | 2 yr | Upper endoscopy or UGIa) |
| Liver | High-risk groupb) aged 40 and over | 6 mo | Ultrasonography and AFP |
| Colorectal | Age 50 and over | 1 yr | FOBTc) |
| Breast | Age 40 and over, women | 2 yr | Mammography |
| Cervix | Age 30 and over, women | 2 yr | Pap smear |
| Survey year | ||||||||
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
| 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | |
| Total (n) | 3,592 | 2,028 | 2,030 | 2,021 | 2,038 | 2,000 | 4,056 | 4,100 |
| Gender | ||||||||
| Male | 42.4 | 41.0 | 40.2 | 39.4 | 40.6 | 41.0 | 41.4 | 41.9 |
| Female | 57.6 | 59.0 | 59.8 | 60.6 | 59.4 | 59.1 | 58.6 | 58.1 |
| Age (yr) | ||||||||
| 30-39a) | 14.1 | 12.0 | 17.6 | 17.8 | 17.7 | 17.0 | 15.9 | 15.5 |
| 40-49 | 35.9 | 41.1 | 34.6 | 34.8 | 35.5 | 35.6 | 34.9 | 33.7 |
| 50-59 | 22.7 | 28.6 | 21.8 | 21.6 | 24.7 | 25.2 | 27.3 | 28.5 |
| 60-69 | 17.3 | 15.6 | 19.1 | 21.9 | 16.4 | 16.4 | 16.8 | 16.1 |
| ≥70 | 10.2 | 2.7 | 6.9 | 3.9 | 5.8 | 5.9 | 5.2 | 6.2 |
| Education (yr) | ||||||||
| ≤8 | 25.8 | 16.4 | 20.9 | 18.2 | 13.6 | 15.1 | 8.1 | 8.2 |
| 9-11 | 15.6 | 16.1 | 15.1 | 14.3 | 16.6 | 11.3 | 10.9 | 10.6 |
| 12-15 | 34.3 | 47.6 | 44.7 | 46.3 | 46.6 | 46.8 | 52.1 | 52.5 |
| ≥16 | 22.6 | 18.5 | 17.6 | 19.1 | 20.7 | 24.9 | 28.8 | 28.7 |
| Monthly household incomeb) ($)c) | ||||||||
| ≤999 | 25.3 | 11.4 | 14.1 | 10 | 9.3 | 9.4 | 4.6 | 4.5 |
| 1,000-2,999 | 39 | 57.1 | 53.1 | 50.5 | 48.8 | 45 | 37.6 | 37.8 |
| ≥3,000 | 18.8 | 29.7 | 29.9 | 38.7 | 40.3 | 44.5 | 57.7 | 57.7 |
| Marital status | ||||||||
| Married | 88.2 | 92.8 | 89.6 | 89.8 | 90.3 | 90.2 | 91.5 | 91.5 |
| Not married | 1.6 | 2.1 | 2.2 | 2.8 | 2.5 | 3.6 | 3 | 3.1 |
| Othersd) | 9.5 | 5.1 | 8.3 | 7.4 | 7.2 | 6.3 | 5.5 | 5.5 |
| Residence area | ||||||||
| Metropolitan | 46.8 | 47.4 | 47.4 | 47.5 | 46.5 | 46.6 | 44.3 | 45.2 |
| Urban | 53.2e) | 39.8 | 40.5 | 40.3 | 44.2 | 44 | 42.2 | 41.6 |
| Rural | 12.7 | 12.1 | 12.2 | 9.3 | 9.4 | 13.5 | 13.1 | |
| Health insurance type | ||||||||
| National Health Insurance | 90.8 | 95.8 | 94.5 | 96.7 | 95.9 | 95.3 | 96.5 | 96.7 |
| Medical Aid Program | 6 | 4.2 | 4.2 | 3.2 | 3.8 | 4.3 | 3.5 | 3.3 |
| Survey year | APC (95% CI) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|||||||||
| 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | ||
| Lifetime screening rate (%)a) | |||||||||
| Stomach | 52.0 | 48.5 | 53.5 | 55.3 | 65.0 | 65.1 | 76.7 | 76.2 | 4.2 (2.8 to 5.6) |
| Liver | 31.8 | 47.7 | 58.3 | 57.6 | 64.8 | 81.3 | 54.2 | 54.3 | 3.2 (-1.6 to 8.0) |
| Colon and rectum | 25.3 | 27.9 | 34.0 | 40.7 | 50.4 | 48.1 | 57.1 | 56.1 | 4.9 (3.7 to 6.1) |
| Breast | 55.9 | 57.4 | 60.2 | 66.4 | 72.7 | 78.1 | 79.5 | 79.0 | 4.0 (3.0 to 4.9) |
| Cervix uteri | 76.8 | 74.0 | 68.0 | 73.6 | 74.4 | 76.1 | 75.0 | 74.8 | 0.2 (-0.9 to 1.3) |
| Screening rate with recommendation (%)b) | |||||||||
| Stomachc) | 39.2 | 39.4 | 43.3 | 45.6 | 53.5 | 56.9 | 65.1 | 64.6 | 4.2 (3.3 to 5.2) |
| Upper endoscopyd) | 32.4 | 32.9 | 33.5 | 37.8 | 44.8 | 49.3 | 58.9 | 58.1 | 4.3 (3.1 to 5.6) |
| UGI seriesd) | 13.0 | 13.1 | 15.2 | 20.4 | 21.1 | 19.5 | 24.9 | 25.3 | 1.9 (1.3 to 2.5) |
| Livere) | 20.0 | 16.3 | 16.5 | 22.7 | 19.7 | 31.3 | 22.9 | 22.9 | 1.1 (-0.5 to 2.7) |
| Colon and rectumf) | 19.9 | 25.4 | 29.4 | 34.1 | 37.9 | 36.7 | 35.5 | 35.3 | 2.2 (0.8 to 3.6) |
| Colonoscopyd),f) | 14.4 | 12.4 | 16.8 | 19.5 | 19.1 | 23.4 | 23.3 | 23.6 | 1.6 (1.1 to 2.2) |
| DCBEd) | 2.8 | 4.1 | 5.3 | 8.7 | 7.0 | 6.1 | 6.1 | 6.0 | 0.4 (-0.2 to 1.0) |
| FOBTd) | 3.8 | 7.2 | 13.6 | 20.2 | 20.9 | 19.0 | 25.9 | 25.0 | 3.1 (1.9 to 4.2) |
| Breastg) | 33.2 | 38.4 | 40.6 | 45.8 | 49.3 | 55.2 | 61.6 | 60.4 | 4.0 (3.0 to 4.9) |
| Cervix uterih) | 58.3 | 57.0 | 54.9 | 57.0 | 59.9 | 63.9 | 62.9 | 62.4 | 0.2 (-0.9 to 1.3) |
APC, annual percent change; CI, confidence interval; UGI, upper gastrointestinal; DCBE, double-contrast barium enema; FOBT, fecal occult blood test. a)Lifetime screening rate is defined as the proportion of respondents who ever underwent the screening test(s), b)Recommended screening rate is defined as the proportion of respondents who fulfilled the screening recommendation criteria among respondents within the targeted age group for the relevant cancer, c)Respondents were restricted to men and women who were 40 years old and over whose last upper endoscopy or UGI series screening was performed within a period of two years, d)Screening rates shown in parentheses are modality-specific rates, e)Respondents were restricted to men and women who were 40 years old and over who were at high risk for liver cancer [hepatitis B virus surface antigen (+), hepatitis C virus antibody (+), or liver cirrhosis] whose last screening with abdominal ultrasonography and serum α-fetoprotein was performed within a period of six months, f)Respondents were restricted to men and women who were 50 years old and over whose last screening with colonoscopy, DCBE, or FOBT was undertaken within a period of 10, five, or one years, respectively. However, before 2009, patients who underwent colonoscopy within a period of five years were regarded as having undergone screening with recommendation, g)Respondents were restricted to women who were 40 years old and over whose last screening with mammography was performed within a period of two years, h)Respondents were restricted to women who were 30 years old and over whose last screening with conventional cytology was undertaken within a period of two years.
| Survey year | APC (95% CI) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | ||
| Lifetime screening rate (%) |
|||||||||
| Stomach | 52.0 | 48.5 | 53.5 | 55.3 | 65.0 | 65.1 | 76.7 | 76.2 | 4.2 (2.8 to 5.6) |
| Liver | 31.8 | 47.7 | 58.3 | 57.6 | 64.8 | 81.3 | 54.2 | 54.3 | 3.2 (-1.6 to 8.0) |
| Colon and rectum | 25.3 | 27.9 | 34.0 | 40.7 | 50.4 | 48.1 | 57.1 | 56.1 | 4.9 (3.7 to 6.1) |
| Breast | 55.9 | 57.4 | 60.2 | 66.4 | 72.7 | 78.1 | 79.5 | 79.0 | 4.0 (3.0 to 4.9) |
| Cervix uteri | 76.8 | 74.0 | 68.0 | 73.6 | 74.4 | 76.1 | 75.0 | 74.8 | 0.2 (-0.9 to 1.3) |
| Screening rate with recommendation (%) |
|||||||||
| Stomach |
39.2 | 39.4 | 43.3 | 45.6 | 53.5 | 56.9 | 65.1 | 64.6 | 4.2 (3.3 to 5.2) |
| Upper endoscopy |
32.4 | 32.9 | 33.5 | 37.8 | 44.8 | 49.3 | 58.9 | 58.1 | 4.3 (3.1 to 5.6) |
| UGI series |
13.0 | 13.1 | 15.2 | 20.4 | 21.1 | 19.5 | 24.9 | 25.3 | 1.9 (1.3 to 2.5) |
| Liver |
20.0 | 16.3 | 16.5 | 22.7 | 19.7 | 31.3 | 22.9 | 22.9 | 1.1 (-0.5 to 2.7) |
| Colon and rectum |
19.9 | 25.4 | 29.4 | 34.1 | 37.9 | 36.7 | 35.5 | 35.3 | 2.2 (0.8 to 3.6) |
| Colonoscopy |
14.4 | 12.4 | 16.8 | 19.5 | 19.1 | 23.4 | 23.3 | 23.6 | 1.6 (1.1 to 2.2) |
| DCBE |
2.8 | 4.1 | 5.3 | 8.7 | 7.0 | 6.1 | 6.1 | 6.0 | 0.4 (-0.2 to 1.0) |
| FOBT |
3.8 | 7.2 | 13.6 | 20.2 | 20.9 | 19.0 | 25.9 | 25.0 | 3.1 (1.9 to 4.2) |
| Breast |
33.2 | 38.4 | 40.6 | 45.8 | 49.3 | 55.2 | 61.6 | 60.4 | 4.0 (3.0 to 4.9) |
| Cervix uteri |
58.3 | 57.0 | 54.9 | 57.0 | 59.9 | 63.9 | 62.9 | 62.4 | 0.2 (-0.9 to 1.3) |
APC, annual percent change; CI, confidence interval; UGI, upper gastrointestinal; DCBE, double-contrast barium enema; FOBT, fecal occult blood test. a)Lifetime screening rate is defined as the proportion of respondents who ever underwent the screening test(s), b)Recommended screening rate is defined as the proportion of respondents who fulfilled the screening recommendation criteria among respondents within the targeted age group for the relevant cancer, c)Respondents were restricted to men and women who were 40 years old and over whose last upper endoscopy or UGI series screening was performed within a period of two years, d)Screening rates shown in parentheses are modality-specific rates, e)Respondents were restricted to men and women who were 40 years old and over who were at high risk for liver cancer [hepatitis B virus surface antigen (+), hepatitis C virus antibody (+), or liver cirrhosis] whose last screening with abdominal ultrasonography and serum α-fetoprotein was performed within a period of six months, f)Respondents were restricted to men and women who were 50 years old and over whose last screening with colonoscopy, DCBE, or FOBT was undertaken within a period of 10, five, or one years, respectively. However, before 2009, patients who underwent colonoscopy within a period of five years were regarded as having undergone screening with recommendation, g)Respondents were restricted to women who were 40 years old and over whose last screening with mammography was performed within a period of two years, h)Respondents were restricted to women who were 30 years old and over whose last screening with conventional cytology was undertaken within a period of two years.
